Bivatuzumab

N/A

Report date: 2026/03/23 20:03:44

Base Information

Drug NameBivatuzumab
Drug Alias Nameanti-CD44BIWA-4anti-CD44 monoclonals
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionCD44 antigen inhibitors
TargetsCD44 antigen
Therapy Area/IndicationsHead and Neck NeoplasmsAdenocarcinoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesC.H. Boehringer Sohn Ag & Co. Kg
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesC.H. Boehringer Sohn Ag & Co. Kg
Active IndicationsN/A
Inactive IndicationsHead and Neck NeoplasmsAdenocarcinoma

Other Information

ATC CodeN/A
Related LinksDrugBank